logo
First Citizens India Expands Operations with New Bengaluru Facility

First Citizens India Expands Operations with New Bengaluru Facility

Entrepreneura day ago

The GCC's mandate covers the delivery of enterprise-grade solutions across core functions critical to the bank's infrastructure and customer engagement strategies
You're reading Entrepreneur India, an international franchise of Entrepreneur Media.
First Citizens India, the Global Capability Centre (GCC) of U.S.-based First Citizens BancShares, Inc., has opened a new office in Bengaluru, signaling a deepened commitment to India as a strategic operations hub. The announcement was made through a press release issued by the company.
The Bengaluru facility features a collaborative and digitally enabled environment designed to support cross-functional teams and foster innovation. The move comes amid the bank's broader push to enhance digital transformation and operational resilience in response to evolving client expectations and market demands.
Jeff Ward, chief strategy officer at First Citizens Bank, who is currently in India to mark the inauguration of the new site, noted the importance of the region in the bank's broader vision. "Our decision to expand our footprint in the established hub of Bengaluru allows us to strategically leverage the country's vast talent pool and directly support the long-term commitment to our enterprise vision," he said.
The expansion reflects the growing role of India in supporting First Citizens Bank's global operations, particularly in areas such as technology, cybersecurity, finance, risk management, and enterprise operations.
First Citizens India has played an increasingly vital role in this transformation journey, integrating the bank's relationship-driven service model into a high-performance global operations framework. The GCC's mandate covers the delivery of enterprise-grade solutions across core functions critical to the bank's infrastructure and customer engagement strategies.
Satya Prakash Ranjan, country head and head of technology at First Citizens India, emphasized the dual role of the new office as a center for delivery and talent development. "As we continue to modernise and scale the bank's technology platforms, this facility and our local team give us the flexibility and environment needed to deliver enterprise-grade solutions across a variety of functions," he said. "We are hiring and welcoming colleagues to help us deliver business solutions based on the bank's shared values."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Backing the Future of Global Biotech: Reynold Lemkins' Strategy Across Borders and Stages
Backing the Future of Global Biotech: Reynold Lemkins' Strategy Across Borders and Stages

Yahoo

time34 minutes ago

  • Yahoo

Backing the Future of Global Biotech: Reynold Lemkins' Strategy Across Borders and Stages

HONG KONG, June 10, 2025--(BUSINESS WIRE)--Reynold Lemkins Group, an international investment firm focused on value-driven cross-border capital deployment, announced the continued advancement of its strategic focus in late-stage healthcare, AI-powered therapeutics, and Asia-centered biotech commercialization. As part of this strategy, Reynold Lemkins recently participated in the IPO of VISEN Pharmaceuticals on the Hong Kong Stock Exchange (HKEX: 02561). VISEN, a biopharmaceutical company specializing in long-acting growth hormone therapies, attracted strong institutional demand and represents the kind of regulatory-validated, commercially scalable business the firm targets. Reynold Lemkins invested alongside globally recognized healthcare investors including HongShan Capital Group (previously Sequoia China), Sofinnova, Vivo Capital, OrbiMed, and WuXi Biologics (HKEX: 2269), reinforcing its commitment to cross-border innovation and long-term capital alignment. This investment underscores Reynold Lemkins' broader strategy of supporting science-driven, late-stage companies with scalable market potential—particularly those operating at the convergence of AI, therapeutics, and Asia-Pacific commercialization. "Our approach focuses on more than capital—we provide strategic insight and cross-border connectivity to help companies scale," said Kris Haoran Liu, President and Chief Investment Officer at Reynold Lemkins Group. "Biotech firms entering public markets need partners who understand both the science and the structure of global growth." With Asia playing an increasingly pivotal role in global healthcare, Reynold Lemkins sees a growing need for capital strategies that link scientific innovation with scalable regional execution. At the same time, the firm closely tracks trends in the U.S. and other mature markets, where biotech companies are navigating longer paths to liquidity and require strategic partners with global reach. Reynold Lemkins positions itself at this intersection—bridging East and West, public and private markets—to support companies shaping the next era of patient-centered care. To learn more, visit follow us on LinkedIn, or explore our insights on Medium. View source version on Contacts Reynold Lemkins Groupreynoldlemkins@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Backing the Future of Global Biotech: Reynold Lemkins' Strategy Across Borders and Stages
Backing the Future of Global Biotech: Reynold Lemkins' Strategy Across Borders and Stages

Business Wire

time38 minutes ago

  • Business Wire

Backing the Future of Global Biotech: Reynold Lemkins' Strategy Across Borders and Stages

HONG KONG--(BUSINESS WIRE)-- Reynold Lemkins Group, an international investment firm focused on value-driven cross-border capital deployment, announced the continued advancement of its strategic focus in late-stage healthcare, AI-powered therapeutics, and Asia-centered biotech commercialization. Bridging East and West in biotech investing, Reynold Lemkins backs science-driven companies with cross-border capital and global scale strategies. Share As part of this strategy, Reynold Lemkins recently participated in the IPO of VISEN Pharmaceuticals on the Hong Kong Stock Exchange (HKEX: 02561). VISEN, a biopharmaceutical company specializing in long-acting growth hormone therapies, attracted strong institutional demand and represents the kind of regulatory-validated, commercially scalable business the firm targets. Reynold Lemkins invested alongside globally recognized healthcare investors including HongShan Capital Group (previously Sequoia China), Sofinnova, Vivo Capital, OrbiMed, and WuXi Biologics (HKEX: 2269), reinforcing its commitment to cross-border innovation and long-term capital alignment. This investment underscores Reynold Lemkins' broader strategy of supporting science-driven, late-stage companies with scalable market potential—particularly those operating at the convergence of AI, therapeutics, and Asia-Pacific commercialization. 'Our approach focuses on more than capital—we provide strategic insight and cross-border connectivity to help companies scale,' said Kris Haoran Liu, President and Chief Investment Officer at Reynold Lemkins Group. 'Biotech firms entering public markets need partners who understand both the science and the structure of global growth.' With Asia playing an increasingly pivotal role in global healthcare, Reynold Lemkins sees a growing need for capital strategies that link scientific innovation with scalable regional execution. At the same time, the firm closely tracks trends in the U.S. and other mature markets, where biotech companies are navigating longer paths to liquidity and require strategic partners with global reach. Reynold Lemkins positions itself at this intersection—bridging East and West, public and private markets—to support companies shaping the next era of patient-centered care. To learn more, visit follow us on LinkedIn, or explore our insights on Medium.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store